GENELUX Corp Files 2023 Annual Report on Form 10-K

TL;DR

<b>GENELUX Corp has submitted its 2023 10-K annual report, detailing financial performance and corporate structure.</b>

AI Summary

GENELUX Corp (GNLX) filed a Annual Report (10-K) with the SEC on March 29, 2024. GENELUX Corp filed its annual report for the fiscal year ending December 31, 2023. The filing is a 10-K, indicating a comprehensive overview of the company's financial performance and condition. The company is incorporated in Delaware and operates within the Pharmaceutical Preparations industry (SIC 2834). Key personnel mentioned in relation to board memberships include John Thomas, James Tyree, Sean Ryder, Paul Scigalla, and Thomas Zindrick. The report covers financial data for the fiscal years 2023, 2022, and 2021, including details on preferred and common stock.

Why It Matters

For investors and stakeholders tracking GENELUX Corp, this filing contains several important signals. This 10-K filing provides investors with a detailed look at GENELUX Corp's financial health, operational results, and strategic positioning for the fiscal year 2023. Understanding the specifics of this report is crucial for assessing the company's current valuation, future prospects, and potential risks within the pharmaceutical preparations sector.

Risk Assessment

Risk Level: medium — GENELUX Corp shows moderate risk based on this filing. The company's financial performance and future outlook are not detailed in the provided header information, making it difficult to assess its current financial health or growth potential.

Analyst Insight

Review the full 10-K filing to analyze GENELUX Corp's financial statements, management discussion, and risk factors to form an investment thesis.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period covered by the 10-K filing)
• 2024-03-29 — Filing Date (Date the 10-K was submitted to the SEC)
• 2023 — Reporting Period (Fiscal year for which the report is filed)
• 2022 — Prior Year (Comparative financial data)
• 2021 — Prior Year (Comparative financial data)

Key Players & Entities

• GENELUX Corp (company) — Filer of the 10-K report
• 2023 (date) — Fiscal year end
• 2024-03-29 (date) — Filing date
• 2834 (industry) — Standard Industrial Classification for Pharmaceutical Preparations
• John Thomas (person) — Board Member
• James Tyree (person) — Board Member
• Sean Ryder (person) — Board Member
• Paul Scigalla (person) — Board Member

FAQ

Industry Context

GENELUX Corp operates in the Pharmaceutical Preparations industry, which is characterized by extensive research and development, regulatory hurdles, and market competition.

Regulatory Implications

As a pharmaceutical company, GENELUX Corp is subject to stringent regulations from bodies like the FDA regarding drug development, manufacturing, and marketing.

What Investors Should Do

1. Thoroughly review the financial statements (income statement, balance sheet, cash flow) within the 10-K.
2. Analyze the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for insights into performance drivers and trends.
3. Examine the 'Risk Factors' section to understand potential challenges and threats to the company's business.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-03-29: Filing Date — Date the 10-K was officially submitted to the SEC.

Year-Over-Year Comparison

This filing is the annual 10-K report for fiscal year 2023, providing a comprehensive update compared to previous filings.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share GNLX The Nasdaq Stock Mar

Filing Documents

• form10-k.htm (10-K) — 3276KB
• ex23-1.htm (EX-23.1) — 4KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 8KB
• ex97.htm (EX-97.1) — 3KB
• form10-k_002.jpg (GRAPHIC) — 158KB
• form10-k_004.jpg (GRAPHIC) — 202KB
• form10-k_005.jpg (GRAPHIC) — 161KB
• form10-k_006.jpg (GRAPHIC) — 65KB
• form10-k_007.jpg (GRAPHIC) — 145KB
• pipe_001.jpg (GRAPHIC) — 110KB
• ph_001.jpg (GRAPHIC) — 91KB
• sclc_001.jpg (GRAPHIC) — 73KB
• ex97_001.jpg (GRAPHIC) — 293KB
• ex97_002.jpg (GRAPHIC) — 401KB
• ex97_003.jpg (GRAPHIC) — 410KB
• ex97_004.jpg (GRAPHIC) — 363KB
• ex97_005.jpg (GRAPHIC) — 71KB
• 0001493152-24-011946.txt (&nbsp;) — 16046KB
• gnlx-20231231.xsd (EX-101.SCH) — 68KB
• gnlx-20231231_cal.xml (EX-101.CAL) — 79KB
• gnlx-20231231_def.xml (EX-101.DEF) — 314KB
• gnlx-20231231_lab.xml (EX-101.LAB) — 618KB
• gnlx-20231231_pre.xml (EX-101.PRE) — 483KB
• form10-k_htm.xml (XML) — 1653KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 31 Item 1B. Unresolved Staff Comments 114 Item 1C. Cybersecurity 114 Item 2.

Properties

Properties 115 Item 3.

Legal Proceedings

Legal Proceedings 115 Item 4. Mine Safety Disclosures 115 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 116 Item 6. Reserved 116 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 117 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 129 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 129 Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosures 129 Item 9A.

Controls and Procedures

Controls and Procedures 129 Item 9B Other Information 130 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 130 PART III Item 10. Directors, Executive Officers and Corporate Governance 131 Item 11.

Executive Compensation

Executive Compensation 133 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 145 Item 13. Certain Relationships and Related Transactions, and Director Independence 146 Item 14. Principal Accountant Fees and Services 147 PART IV Item 15. Exhibits and Financial Statement Schedules 149 Item 16. Form 10-K summary 150

SIGNATURES

SIGNATURES 151 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (this Annual Report) contains forward-looking statements within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than financial position, business strategy, research and development costs; the anticipated timing, costs and conduct of our clinical trials for our only product candidate, Olvi-Vec; the timing and likelihood of regulatory filings and approvals for Olvi-Vec; our ability to commercialize Olvi-Vec, if approved; the pricing and reimbursement of Olvi-Vec, if approved; the potential benefits of strategic collaborations and our ability to enter into strategic arrangements; the timing and likelihood of success, plans and objectives of management for future operations; future results of anticipated product development efforts; and our expected future financing needs, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we bel

View Full Filing

View this 10-K filing on SEC EDGAR